Liquiritigenin

Liquiritigenin is a flavanone compound found in licorice root that acts as a selective estrogen receptor beta (ERβ) agonist with an EC50 of 36.5 nM. This selective mechanism provides estrogenic benefits without stimulating proliferative pathways associated with breast cancer risk.

Origin & History

Liquiritigenin is a flavanone compound with hydroxy groups at the 4'- and 7-positions, primarily isolated from the roots of Glycyrrhiza uralensis (Chinese licorice) and Glycyrrhiza glabra. It is extracted using solvents like chloroform, dichloromethane, or ethyl acetate from dried licorice roots.

Historical & Cultural Context

While liquiritigenin itself lacks documented standalone traditional use, it occurs naturally in Glycyrrhiza species that have been used in Traditional Chinese Medicine for various ailments. The compound is found in licorice roots alongside related flavonoids like isoliquiritigenin and liquiritin.

Health Benefits

• Selective estrogen receptor beta (ERβ) activation with EC50 of 36.5 nM, promoting beneficial estrogenic effects without ERα proliferation (preclinical evidence only)
• Non-proliferative estrogenic activity that doesn't stimulate breast cancer cell growth in MCF-7 cells (in vitro studies)
• Potential age-related disease applications through ERβ-specific transcription (theoretical based on mechanism studies)
• Distinct from harmful estrogenic effects by avoiding c-myc and cyclin D1 gene activation (cellular studies)
• Possible anti-inflammatory properties as part of licorice's bioactive profile (traditional use inference, no direct clinical evidence)

How It Works

Liquiritigenin selectively binds to and activates estrogen receptor beta (ERβ) with high affinity (EC50 of 36.5 nM) while showing minimal activity at estrogen receptor alpha (ERα). This selective activation promotes beneficial estrogenic signaling pathways including bone protection and cardiovascular benefits without triggering proliferative responses in breast and endometrial tissues. The compound demonstrates non-proliferative estrogenic activity in MCF-7 breast cancer cells, indicating safer estrogenic modulation.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specifically on liquiritigenin were identified in the available research. Current evidence is limited to preclinical studies examining its ERβ selectivity and cellular mechanisms, with no PMIDs available for human studies.

Clinical Summary

Current evidence for liquiritigenin consists primarily of preclinical in vitro and animal studies, with limited human clinical data available. Laboratory studies demonstrate selective ERβ activation at nanomolar concentrations and non-proliferative effects in breast cancer cell lines. Animal studies suggest potential benefits for menopausal symptoms and bone health through selective estrogen receptor modulation. Human clinical trials are needed to establish therapeutic efficacy, optimal dosing, and safety profiles in target populations.

Nutritional Profile

Liquiritigenin is a flavanone aglycone compound (molecular weight: 256.25 g/mol) derived primarily from licorice root (Glycyrrhiza species), not a conventional nutrient source with macronutrient or micronutrient content. As a pure bioactive compound, it contains no protein, fat, fiber, or vitamins. Bioactive concentration: found in licorice root at approximately 0.1–0.5% dry weight depending on species and extraction method. Oral bioavailability is limited due to first-pass metabolism and poor aqueous solubility; it undergoes intestinal glucuronidation and sulfation, reducing systemic exposure. Gut microbiota can convert the glycoside liquiritin to liquiritigenin via beta-glucosidase activity, meaning colonic conversion is a meaningful bioavailability pathway. Peak plasma concentrations in animal models range from 50–200 ng/mL following oral dosing at 10–50 mg/kg. No established dietary reference intake or therapeutic dose has been validated in human clinical trials.

Preparation & Dosage

No clinically studied dosage ranges for liquiritigenin in humans have been established. Preclinical studies use purified compounds, but human dosing, standardization details, and recommended forms (extract, powder) are not available. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Liquiritigenin pairs well with genistein (soy isoflavone), which also demonstrates ERβ selectivity; co-administration may produce additive ERβ transcriptional activation while maintaining low ERα stimulation, potentially relevant for menopausal symptom management without proliferative risk. Piperine (black pepper extract, 5–20 mg) inhibits glucuronidation enzymes (UGT1A family) that rapidly metabolize liquiritigenin, meaningfully enhancing its oral bioavailability — a mechanism mirroring its well-documented enhancement of curcumin absorption. Resveratrol complements liquiritigenin through overlapping SIRT1 activation and ERβ-mediated neuroprotective pathways, potentially offering additive effects in age-related cognitive applications; additionally, quercetin shares flavonoid metabolism pathways and may competitively reduce liquiritigenin's conjugation burden in the gut, modestly prolonging its active circulating half-life.

Safety & Interactions

Safety data for liquiritigenin supplementation in humans is limited due to lack of comprehensive clinical trials. As an estrogenic compound, it may theoretically interact with hormone replacement therapy, birth control pills, and hormone-sensitive medications. Individuals with hormone-sensitive conditions including breast, ovarian, or endometrial cancers should exercise caution. Pregnancy and breastfeeding safety has not been established, and use should be avoided during these periods without medical supervision.